BioSpace News Archive

Almirall, S.A. (ALM) announced today that it has signed an agreement with the French Authorities to make the biologic treatment ILUMETRI® (tildrakizumab), a high-affinity IL-23p19 monoclonal antibody, available in France for the treatment of adult patients with severe plaque psoriasis who are candidates for biological systemic therapy.

Aro Biotherapeutics today announced the appointments of Christopher K. Mirabelli, Ph.D., to its Board of Directors and Masad J. Damha, Ph.D., to its Scientific Advisory Board. Drs. Mirabelli and Damha will provide strategic and scientific counsel on the development of novel Centyrin-RNA therapeutic candidates. “We are excited to welcome Chris, a well-recognized leader in drug development, to our Board of Directors. As

Cedilla Therapeutics, a private biotechnology company developing targeted small molecules for the treatment of cancer and other diseases caused by protein dysregulation, today announced the closing of a $57.6 million Series B financing. The financing was co-led by Casdin Capital and Boxer Capital of Tavi

Northwest Specialty Hospital is one of the first hospitals in the world to have the newest version of this advanced technology, enabling a fully navigated spine procedures from start to finish such as a lateral lumbar interbody fusion or a transforaminal lumbar interbody fusion procedure.

Aesthetic Medical International Holdings Group Limited (the “Company”) (NASDAQ: AIH), a leading provider of aesthetic medical services in China, today announced that its board of directors has authorized a share repurchase program under which the Company may repurchase up to US$6.0 million worth of its American depositary shares over the next 12-month period, effective until October 12, 2021,

Salarius Pharmaceuticals, LLC , a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Executive Officer, David Arthur, will present at the BIO Investor Forum Digital conference taking place Tuesday, October 13, 2020 to Thursday, October 15, 2020. The presentation will be available on demand during the virtual event for all registered attendees. During the presentation, Mr. Arthur

FH Ortho Inc, a well-established innovative orthopedic medical device company, is pleased to announce the FDA clearance of Telegraph Evolution, a next generation humeral nailing system for use in proximal and/or mid-shaft humeral fractures. Chris Valois, General Manager of FH Ortho Inc said, “We are seeing a trend in the US towards humeral fracture nails and away from plating due to advancements in instrumentation and perceived improved patient outc

TORONTO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- CB2 Insights (the “ Company ” or “ CB2 ”) (CSE:CBII OTCQB:CBIIF), one of the largest integrative healthcare systems in the United States, is pleased to announce it will be participating in the Gravitas Technology and Diversified Investor Day taking place Thursday, October 15 th , 2020 virtually. CB2’s Chief Executive Officer, Pradyum Sekar, is scheduled to present on Thursday, October 15 th at 3:00 PM EST. Mr. Sekar will also be fielding investor qu

- Novellus’s iMSCs are derived from a single donor using its patented mRNA-based, footprint-free cell reprogramming technology - iMSCs overcome the significant challenges of limited supply and low potency associated with donor-derived MSCs [13-October-2020] CAMBRIDGE, Mass. , Oct. 13, 2020 /PRNewswire/ -- Novellus Therapeutics (“Novellus”), an engineered cel

IntegriChain, a leading data and managed services company helping Life Sciences manufacturers deliver access to innovative therapies that significantly improve patient lives, today announced the availability of GTN Analytics, a new offering complementing the company’s Gross-to-Net (GTN) applications and managed services.